10 / 18
7
t h
E u r o p e a n C o n g r e s s o n
Obesity and
Eating Disorder
Obesity 2018
Journal of Obesity & Eating Disorders
ISSN 2471-8203
A p r i l 1 2 - 1 3 , 2 0 1 8
Am s t e r d a m , N e t h e r l a n d s
Page 52
M
any obesity related genes have been proposed as
targets for the treatment of obesity and type II diabetes.
However, these obesity genes did not provide efficient drug
therapy mainly due to the redundancy of the biochemical
pathway involved in obesity and the lack of specificity and the
lack of association of the gene target and the lean phenotype.
It is therefore a challenge to identify crucial gene(s) targets
involved in energy metabolism associated with “lean or
starvation phenotype”. Congenital enteropeptidase deficiency
is an extremely rare pathology which answers all the criteria.
We have identified several lead compounds that are active in
vitro against the enteropeptidase and shows very promising
results in a mouse model that will be discussed
iharosh@obetherapy.comThinking outside the box for target identification
and validation for obesity and type II diabetes
treatment
Itzik Harosh
1
and Marco Ciufolini
2
1
ObeTherapy, France
2
University of British Columbia, British Columbia
J Obes Eat Disord 2018, Volume: 4
DOI: 10.21767/2471-8203-C1-009